Bipolar disorder is severe mental disorder and typically consists of both manic and depressive episodes separated by periods of normal mood. In the case of bipolar disorder, the diagnosis rate is low, and misdiagnosis and underdiagnosis rates are high. Quetiapine was listed in the lecture as one of the first-line treatments for bipolar depression in the CANMAT/ISBD 2018 guidelines. Luye Pharma, the event organizer, has long been working in the central nervous system (CNS) therapeutic area. Zhou Jun, Vice President of Marketing at Luye Pharma (International), said,“It is encouraging to see the growing recognition of this academic platform among physicians as we expand to cover more global regions.

Source: The North Africa Journal November 25, 2021 10:07 UTC